<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A modified regimen of high-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (<z:chebi fb="3" ids="3498">CTX</z:chebi>) plus <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (CsA) was adopted for patients with severe or very severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, and the effectiveness was compared with a regimen of antithymocyte globulin (ATG) plus CsA </plain></SENT>
<SENT sid="1" pm="."><plain>A total of 121 patients enrolled in this study received either <z:chebi fb="3" ids="3498">CTX</z:chebi> plus CsA (<z:chebi fb="3" ids="3498">CTX</z:chebi> group, 48 cases) or ATG plus CsA (ATG group, 73 cases) </plain></SENT>
<SENT sid="2" pm="."><plain>The early <z:hpo ids='HP_0011420'>death</z:hpo> rate was 4.2% in the <z:chebi fb="3" ids="3498">CTX</z:chebi> group and 8.2% in the ATG group, showing no significant difference (p = 0.312) </plain></SENT>
<SENT sid="3" pm="."><plain>The total response rate in the <z:chebi fb="3" ids="3498">CTX</z:chebi> and ATG groups was 54.2% and 57.5% at 3 months, 64.6% and 72.6% at 6 months, and 72.9% and 78.1% at 12 months, respectively (p &gt; 0.05) </plain></SENT>
<SENT sid="4" pm="."><plain>The overall 5-year survival rate was 81.2% and 80.7%, and the event-free survival rate was 68.2% and 67.3% in the <z:chebi fb="3" ids="3498">CTX</z:chebi> and ATG groups, respectively (p &gt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>The total medical cost of the <z:chebi fb="3" ids="3498">CTX</z:chebi> group was 54.8% less than that of ATG regimen (p = 0.000) </plain></SENT>
<SENT sid="6" pm="."><plain>In summary, treatment of severe or very severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> with <z:chebi fb="3" ids="3498">CTX</z:chebi> plus CsA has effectiveness that is comparable to a conventional regimen and less costly </plain></SENT>
</text></document>